Publish in OALib Journal
APC: Only $99
Objective: Molecular targeting therapy
has not been generally established in head and neck squamous cell carcinoma
(HNSCC) except for cetuximab treatment for targeting epidermal growth factor
receptor (EGFR). We analyzed alterations of the TP53, KRAS2, and EGFR genes
in Japanese HNSCC to identify subpopulations of tumors potentially susceptible
or not susceptible to specific therapy based on their genetic alterations.
Materials and Methods: A total of 56 Japanese subjects were included in this
study. Genomic DNA of exons 5 - 9 of the TP53, exons 1 and 2 of the KRAS2,
exons 19 - 22 of the EGFR, and their flanking sequences were
amplified by polymerase chain reaction (PCR) followed by direct sequencing.
Splicing variants of EGFR were examined by reverse
transcription (RT)-PCR. Results: Mutations of the TP53 and KRAS genes
were detected in 25 (45%) and 2 (4%) of 56 HNSCC cases, respectively, while
neither mutation nor splicing variant of EGFR was observed.